BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

Free Newsletters
My Subscriptions

News by Subject
News by Disease
News by Date
Search News
Post Your News

Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Pharm Country
  Bio NC
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™


Company Profiles

Research Store

Research Events
Post an Event
Real Estate
Business Opportunities

PLoS By Category | Recent PLoS Articles
Anesthesiology and Pain Management - Biochemistry - Biophysics - Biotechnology - Cardiovascular Disorders - Chemical Biology - Chemistry - Computer Science - Critical Care and Emergency Medicine - Dermatology - Diabetes and Endocrinology - Ecology - Evidence-Based Healthcare - Gastroenterology and Hepatology - Geriatrics - Hematology - Immunology - Infectious Diseases - Mathematics - Mental Health - Microbiology - Molecular Biology - Nephrology - Neurological Disorders - Neuroscience - Non-Clinical Medicine - Nutrition - Obstetrics - Oncology - Ophthalmology - Otolaryngology - Pathology - Pediatrics and Child Health - Pharmacology - Physics - Physiology - Public Health and Epidemiology - Radiology and Medical Imaging - Respiratory Medicine - Rheumatology - Science Policy - Surgery - Urology - Virology - Women's Health

Novel, Objective, Multivariate Biomarkers Composed of Plasma Amino Acid Profiles for the Diagnosis and Assessment of Inflammatory Bowel Disease
Published: Tuesday, January 31, 2012
Author: Tadakazu Hisamatsu et al.

by Tadakazu Hisamatsu, Susumu Okamoto, Masaki Hashimoto, Takahiko Muramatsu, Ayatoshi Andou, Michihide Uo, Mina T. Kitazume, Katsuyoshi Matsuoka, Tomoharu Yajima, Nagamu Inoue, Takanori Kanai, Haruhiko Ogata, Yasushi Iwao, Minoru Yamakado, Ryosei Sakai, Nobukazu Ono, Toshihiko Ando, Manabu Suzuki, Toshifumi Hibi


Inflammatory bowel disease (IBD) is a chronic intestinal disorder that is associated with a limited number of clinical biomarkers. In order to facilitate the diagnosis of IBD and assess its disease activity, we investigated the potential of novel multivariate indexes using statistical modeling of plasma amino acid concentrations (aminogram).

Methodology and Principal Findings

We measured fasting plasma aminograms in 387 IBD patients (Crohn's disease (CD), n?=?165; ulcerative colitis (UC), n?=?222) and 210 healthy controls. Based on Fisher linear classifiers, multivariate indexes were developed from the aminogram in discovery samples (CD, n?=?102; UC, n?=?102; age and sex-matched healthy controls, n?=?102) and internally validated. The indexes were used to discriminate between CD or UC patients and healthy controls, as well as between patients with active disease and those in remission. We assessed index performances using the area under the curve of the receiver operating characteristic (ROC AUC). We observed significant alterations to the plasma aminogram, including histidine and tryptophan. The multivariate indexes established from plasma aminograms were able to distinguish CD or UC patients from healthy controls with ROC AUCs of 0.940 (95% confidence interval (CI): 0.898–0.983) and 0.894 (95%CI: 0.853–0.935), respectively in validation samples (CD, n?=?63; UC, n?=?120; healthy controls, n?=?108). In addition, other indexes appeared to be a measure of disease activity. These indexes distinguished active CD or UC patients from each remission patients with ROC AUCs of 0.894 (95%CI: 0.853–0.935) and 0.849 (95%CI: 0.770–0.928), and correlated with clinical disease activity indexes for CD (rs?=?0.592, 95%CI: 0.385–0.742, p<0.001) or UC (rs?=?0.598, 95%CI: 0.452–0.713, p<0.001), respectively.

Conclusions and Significance

In this study, we demonstrated that established multivariate indexes composed of plasma amino acid profiles can serve as novel, non-invasive, objective biomarkers for the diagnosis and monitoring of IBD, providing us with new insights into the pathophysiology of the disease.